Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Why XOM is close to an ideal option trading candidate

XOM has a hugely active options series, trades in both monthly and weekly expiration series and has bid / ask spreads that are just a few pennies wide. One of the most interesting aspects of options is the myriad opportunities presented for high probability trades for thos...
J.W. Jones | February 6, 2013 |

Immuno-Oncology Firm Expands Agreement with AbbVie

The revisions to the existing arrangement between the two U.S. firms are discussed in a ROTH Capital Partners report. In a Nov. 21 research note, ROTH Capital Partners analyst Zegbeh Jallah reported that Harpoon Therapeutics Inc. (HARP:NASDAQ) and AbbVie Inc. (ABBV...
Streetwise Reports | December 5, 2019 |

Rare Diseases Biotech Provides Opportunity

A ROTH Capital Partners report discussed why the stock price is at its current level and noted upcoming catalysts for the company. In a March 15 research note, ROTH Capital Partners analyst Yasmeen Rahimi indicated that the recent drop in Soleno Therapeutics Inc.'s (SL...
Streetwise Reports | March 22, 2019 |

Biopharma's Early Data Show Immunotherapy's Efficacy in Ovarian Cancer

The "encouraging" data for this drug candidate as a monotherapy is the focus of an H.C. Wainwright & Co. report. In a March 26 research note, analyst Joseph Pantginis reported that IMV Inc.'s (IMV:TSX; IMMVD:OTCQX) preliminary monotherapy data confirmed the efficacy o...
Streetwise Reports | April 1, 2019 |

San Diego Biopharma Features 'Strong and Balanced Pipeline'

An H.C. Wainwright & Co. report discussed what sets this company's asset apart from similar products. In a March 21 research note, H.C. Wainwright & Co. analyst Andrew Fein wrote that MEI Pharma Inc.'s (MEIP:NASDAQ) oral PK3K delta inhibitor, ME-401, differentiates it...
Streetwise Reports | March 28, 2019 |

Biopharma Starts 'Key Catalyst Period,' H2/19, with Clinical Trial in New Indication

A study description and expected data readouts this year are provided in a ROTH Capital Partners report. In a July 8 research note, ROTH Capital Partners analyst Yasmeen Rahimi reported that Enanta Pharmaceuticals Inc. (ENTA:NASDAQ) kicked off Q2/19 by...
Streetwise Reports | July 11, 2019 |

WPX Energy Raises Full-Year Oil Guidance by 4% and Initiates $400M Stock Repurchase Plan

Shares of WPX Energy are trading higher after it released second quarter earnings and raised full-year oil guidance by 4%. The firm also announced it is initiating a 24-month, $400 million share repurchase program. After the close of trading yesterday, W...
Streetwise Reports | August 7, 2019 |

China Social Media Firm Gains 55 Million Monthly Active Users

Weibo Corp. (WB:NASDAQ) , a leading Chinese social media platform company with nearly 500 million monthly active users, today announced its unaudited financial results for the second quarter ended June 30, 2019. In the report, the firm reported total n...
Streetwise Reports | August 20, 2019 |

Analyst Raises Target Price of Canadian Miner Given 'Continued Momentum'

Key points management made on a recent investor tour are presented in a BMO Capital Markets report. In a Sept. 5 research note, analyst Andrew Kaip reported that BMO Capital Markets raised its target price on Pretium Resources Inc. (PVG:TSX; PVG:NYSE) to CA$24 per s...
Streetwise Reports | September 12, 2019 |

Ra Pharmaceuticals Shares Up 100% Following $2.1 Billion Takeover Bid

Shares of Ra Pharmaceuticals doubled today after the firm announced that it will be acquired by Belgian firm UCB for $48 per share in an all cash deal. Prior to the market open this morning Ra Pharmaceuticals Inc. (RARX:NASDAQ) and Brussels-based UCB (UCB:Euronext)...
Streetwise Reports | October 11, 2019 |
1 2 3 4 5 6 7 8 9 10 ...